SGN-15

SGN-15

A formulation of a monoclonal antibody bound to a cytotoxic antibiotic (BR96-doxorubicin) which made it to Phase-II trials with “encouraging trends” reported for managing lung cancer. Its sponsorship ceased in 2005.
References in periodicals archive ?
The number of clinical trials was expanded with the initiation of the SGN-15 study in lung cancer.
SGN-15 is presently being tested in phase II trials for the treatment of breast, colon, lung and prostate cancers.
Reported data on phase II clinical trials of SGN-15 at the 11th World Conference on Lung Cancer.
Avodart, Zoladex, Proscar, Casodex, Taxotere, Satraplatin, Plenaxis, EULEXIN, Trelstar Depot, Trelstar LA, Viadur, Gleevec, Avastin, Herceptin, Atrasentan, Acapodene, Actimid, OSI-461, Revimid, Eladem, GTI-2501, ILX-651, calcitrol, Genasense, Provenge , GVAX, SGN-15, Thalomid, Velcade, Lupron Depot, Histrelin, Eligard, ILX651, Vitaxin, J591, CG7870, BBR-3576, PCK3145, Leuvectin, Leuprolide, ProMaxx-100, Osaterone, Prinomastat, BLP25, Metaret, Chimax, Drogenil, Flutamide, EULEXIN, Onconase, IM862, MDX-010, Erbitux, Eladem, GTI-2040, Apomine, Eflornithine, Doxil, GTI-2501, Thalidomide, TG4010, KRX-0401, Yondelis, TRICOM Vaccine, Zarnestra
Nasdaq:SGEN) today reported data from its phase II clinical trials of SGN-15 at the 11th World Conference on Lung Cancer being held in Barcelona, Spain.
This issue presents the latest data on utilizing a combinatory therapeutic strategy of docetaxel and different investigational drugs such as Avastin, Herceptin, GTI-2501, ILX-651, calcitrol, Genasense, Gleevec, SGN-15, Thalomid and Velcade.
The company has built a diverse portfolio of product candidates targeted to many types of cancer, including three being tested in multiple ongoing clinical trials, SGN-30, SGN-15 and SGN-40, and four in preclinical development, SGN-35, SGN-70, SGN-75 and SGN-17/19.
Among novel targeted cytotoxic antibiotics are biotinylated CBI-bearing CC-1065 analogs, bispecific monoclonal antibodies (MAb), cytotoxic peptide conjugates targeted to their receptors on tumors (AN-215, AN-238, D-26232, C-terminal gastrin heptapeptide-targeted cytotoxics), CMC-544, Davanat-2, HPMA-HA-DOX, immunoliposomes (CA15-3 targeting, anti-HER2/doxorubicin immunoliposomes, EGFr-targeted/epirubicin immunoliposomes, and MCC-465), SGN-15, and vitamin-mediated targeted delivery.
This increase was primarily driven by expanded clinical trial activity for the company's SGN-30, SGN-40 and SGN-15 product candidates, as well as growth of the company's workforce and related laboratory expenses.
approximately $500 million from SGN-15 and SGN-10 based on a market
This increase was primarily driven by higher levels of contract manufacturing of clinical grade materials and expanded clinical trial activity for the company's SGN-30, SGN-40 and SGN-15 product candidates.
Siegall will present an overview of the company focusing on its three clinical product candidates, SGN-30, SGN-15 and SGN-40, its preclinical programs and its industry-leading antibody-drug conjugate (ADC) technology.